Current status of neuroprotection trials for traumatic brain injury: Lessons from animal models and clinical studies

Neurosurgery

Volumn 45, Issue 2, 1999, Pages 207-220

  Bullock, M Ross ^a   Lyeth, Bruce G ^b   Muizelaar, J Paul ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; Clinical trials; Glasgow Outcome Scale; Neuroprotection; Therapy; Traumatic brain injury

Indexed keywords

4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; APTIGANEL; ATROPINE; BARBITURIC ACID DERIVATIVE; BIPERIDEN; CORTICOSTEROID; DELTIBANT; DEXANABINOL; DEXTROMETHORPHAN; DEXTRORPHAN; DIZOCILPINE; ELIPRODIL; KETAMINE; MANNITOL; N METHYL DEXTRO ASPARTIC ACID; NIMODIPINE; OMEGA CONOTOXIN MVIIA; PENTOBARBITAL; PHENCYCLIDINE; SCAVENGER; TIRILAZAD; TROMETAMOL;

ANIMAL MODEL; BRAIN CONTUSION; BRAIN HEMATOMA; BRAIN INJURY; BRAIN ISCHEMIA; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MICRODIALYSIS; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ANIMALS; BRAIN INJURIES; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 0032839242     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199908000-00001     Document Type: Review

References (82)

1. Adams JH, Graham DI, Gennarelli TA: Head injury in man and experimental animals: Neuropathology. Acta Neurochir Suppl (Wien) 32:S15-S30, 1983.
2. Adams JH, Graham DI, Gennarelli TA: Contemporary neuropathological considerations regarding brain damage in head injury, in Becker DP, Povlishock JT (eds): Central Nervous System Trauma Status Report: 1985. Richmond, William Byrd Press, 1985, pp 65-77.
3. Astrup J, Siesjö BK, Symon L: Thresholds in cerebral ischemia: The ischemic penumbra. Stroke 12:723-725, 1981.
4. Bergsneider M, Hovda DA, Shalmon E, Kelly DF, Vespa PM, Martin NA, Phelps ME, McArthur DL, Caron MJ, Kraus JF, Becker DP: Cerebral hyperglycolysis following severe traumatic brain injury in humans: A positron emission tomography study. J Neurosurg 86:241-251, 1997.
5. Bouma GJ, Muizelaar JP, Stringer WA, Choi SC, Fatouros PP, Young HF: Ultra-early evaluation of regional cerebral blood flow in severely head-injured patients using xenon-enhanced computerized tomography. J Neurosurg 77:360-368, 1992.
6. Branston NM, Symon L, Crockard HA, Pasztor E: Relationships between the cortical evoked potential and local cortical blood flow following acute middle cerebral artery occlusion. Exp Neurol 45:195-208, 1974.
7. Broaddus WC, Prahbu SS, Gillies GT, Neal J, Conrad WS, Chen ZJ, Fillmore HL: Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. J Neurosurg 88:734-742, 1998.
8. Brooks DN, Hosie J, Bond MR, Jennett B, Aughton M: Cognitive sequelae of severe head injury in relation to the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry 49:549-553, 1986.
9. Bullock R: Strategies for neuroprotection with glutamate antagonists: Extrapolating from evidence taken from the first stroke and head injury studies. Ann N Y Acad Sci 765:272-278, 1995.
10. Bullock R, Zauner A, Tsuji O, Woodward JJ, Marmarou AT, Young HF: Patterns of excitatory amino acid release and ionic flux after severe human head trauma, in Tsubokawa T, Marmarou A, Robertson C, Teasdale G (eds): Neurochemical Monitoring in the Intensive Care Unit. Tokyo, Springer-Verlag, 1995, pp 64-77.
11. Clifton GL, Allen S, Barrodale P, Plenger P, Berry J, Koch S, Fletcher J, Hayes RL, Choi SC: A Phase II study of moderate hypothermia in severe brain injury. J Neurotrauma 10:263-271, 1993.
12. Clifton GL, Kreutzer JS, Choi SC, Devany CW, Eisenberg HM, Foulkes MA, Jane JA, Marmarou A, Marshall LF: Relationship between Glasgow Outcome Scale and neuropsychological measures after brain injury. Neurosurgery 33:34-39, 1993.
13. Delahunty TM: Mild traumatic brain injury enhances muscarinic receptor-linked inositol phosphate production in rat hippocampus. Brain Res 594:307-310, 1992.
14. Di X, Harpold T, Watson JC, Bullock R: Excitotoxic damage in neurotrauma: Fact or fiction. Restor Neurol Neurosci 9:231-241, 1996.
15. Drummond MF, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK, Oxford University Press, 1987.
16. Dumas R, Woitinas F, Kutnowski M, Nikolic I, Berberich R, Abedinpour F, Zoeckler S, Gregoire F, Jerkovic M, Egberts JFM, Stiekema JCJ: A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke. Age Ageing 23:512-516, 1994.
17. Eisenberg HM, Frankowski RF, Contant CF, Marshall LF, Walker MD: High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg 69:15-23, 1988.
18. European Study Group on Nimodipine in Severe Head Injury: A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J Neurosurg 80:797-804, 1994.
19. Faden AI, Demediuk P, Panter SS, Vink R: The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244:798-800, 1989.
20. Faden AI, Takemori AE, Portoghese TS: κ-Selective opiate antagonist nor-binaltorphimine improves outcome after traumatic spinal cord injury in rats. Cent Nerv Syst Trauma 4:227-237, 1987.
21. Gentleman SM, Roberts GW, Gennarelli TA, Maxwell WL, Adams JH, Kerr S, Graham DI: Axonal injury: A universal consequence of fatal closed head injury? Acta Neuropathol (Berl) 89:537-543, 1995.
22. Golding EM, Vink R: Efficacy of competitive vs noncompetitive blockade of the NMDA channel following traumatic brain injury. Mol Chem Neuropathol 24:137-150, 1995.
23. Gopinath SP, Robertson CS, Contant CF, Hayes C, Feldman Z, Narayan RK, Grossman RG: Jugular venous desaturation and outcome after head injury. J Neurol Neurosurg Psychiatry 57: 717-723, 1994.
24. Graham DI: The pathology of brain ischemia and possibilities for therapeutical intervention. Br J Anaesth 57:3-25, 1985.
25. Grumme T, Baethmann A, Kolodziejczyk D, Krimmer J, Fischer M, von Eisenhart Rothe B, Pelka R, Bennefeld H, Pèollauer E, Kostron H, Leheta F, Necek S, Neeser G, Sachsenheimer W, Ommeraurer J, Verhoeven F: Treatment of patients with severe head injury by triamcinolone: A prospective, controlled multicenter clinical trial of 396 cases. Res Exp Med (Berl) 195:217-229, 1995.
26. Hamm RJ, O'Dell DM, Pike BR, Lyeth BG: Cognitive impairment following traumatic brain injury: The effect of pre-and post-injury administration of scopolamine and MK-801. J Cognitive Brain Res 1:223-226, 1993.
27. Harders A, Kakarieka A, Braakman R: Traumatic subarachnoid hemorrhage and its treatment with nimodipine: German tSAH Study Group. J Neurosurg 85:82-89, 1996.
28. Hayes RL, Jenkins LW, Lyeth BG, Balster RL, Robinson SE, Clifton GL, Stubbins JF, Young HF: Pretreatment with phencyclidine, an N-methyl-D-aspartate antagonist, attenuates long-term behavioral deficits in the rat produced by traumatic brain injury. J Neurotrauma 5:259-274, 1988.
29. Heppner F, Diemath HE: Clinical experience with anticholinergic therapy of covered craniocerebral injuries. Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed 61:257-265, 1958.
30. Inglis F, Kuroda Y, Bullock R: Glucose hypermetabolism after acute subdural hematoma is ameliorated by a competitive NMDA antagonist. J Neurotrauma 9:75-84, 1992.
31. Jennett B, Snoek J, Bond MR, Brooks N: Disability after severe head injury: Observations on the use of the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry 44:285-293, 1981.
32. Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, Ojemann RG: Threshold of focal ischemia in awake monkeys. J Neurosurg 54:773-782, 1981.
33. Katayama Y, Becker DP, Tamura T, Hovda DA: Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. J Neurosurg 73:889-900, 1990.
34. Kawamata T, Katayama Y, Hovda DA, Yoshino A, Becker DP: Administration of excitatory amino acid antagonists via microdialysis attenuates the increase in glucose utilization seen following concussive brain injury. J Cereb Blood Flow Metab 12:12-24, 1992.
35. Kuroda Y, Bullock R: Failure of cerebral blood flow: Metabolism coupling after acute subdural hematoma in the rat. Neurosurgery 31:1062-1071, 1992.
36. Kuroda Y, Fujisawa H, Strebel S, Graham DI, Bullock R: Effect of neuroprotective N-methyl-D-aspartate antagonists on increased intracranial pressure: Studies in the rat acute subdural hematoma model. Neurosurgery 35:106-112, 1994.
37. Landolt H, Langemann H, Mendelowirsch A, Gratzl O: Neurochemical monitoring and on-line pH measurements using brain microdialysis in patients in intensive care. Acta Neurochir Suppl (Wien) 60:475-478, 1994.
38. Lyeth BG, Dixon CE, Jenkins LW, Hamm RJ, Alberico A, Young HF, Stonnington HH, Hayes RL: Effects of scopolamine treatment on long-term behavioral deficits following concussive brain injury to the rat. Brain Res 452:39-48, 1988.
39. Maas AIR, Braakman R, Schouten HJA, Minderhoud JM, Van Zomeren AH: Agreement between physicians on assessment of outcome following severe head injury. J Neurosurg 58:321-325, 1983.
40. Maier-Hauff K, Baethmann AJ, Lange M, Schurer L, Unterberg A: The kallikrein-kinin system as mediator in vasogenic brain edema: Part 2 - Studies on kinin formation in focal and perifocal brain tissue. J Neurosurg 61:97-106, 1984.
41. Marion DW, Penrod LE, Kelsey SF, Obrist WD, Kochanek PM, Palmer AM, Wisniewski SR, DeKosky ST: Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med 336:540-546, 1997.
42. Marmarou A: Conduct of head injury trials in the United States: The American Brain Injury Consortium (ABIC). Acta Neurochir Suppl (Wien) 66:118-121, 1996.
43. Marshall LF, Marshall SB: Pitfalls and advances from the international tirilazad trial in moderate and severe head injury. J Neurotrauma 12:929-932, 1995.
44. Marshall LF, Maas AIR, Marshall SB, Bricolo A, Fearnside M, Iannotti F, Klauber MR, Lagarrigue J, Lobato R, Persson L, Pickard JD, Piek J, Servadei F, Wellis GN, Morris GF, Means ED, Musch B: A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J Neurosurg 89:519-525, 1998.
45. Maxwell WL, Povlishock JT, Graham DI: A mechanistic analysis of nondisruptive axonal injury. J Neurotrauma 14:419-440, 1997.
46. McIntosh TK, Vink R, Soares H, Hayes R, Simon R: Effects of the N-methyl-D-aspartate receptor blocker MK-801 on neurologic function after experimental brain injury. J Neurotrauma 6:247-259, 1989.
47. McIntosh TK, Vink R, Soares H, Hayes R, Simon R: Effect of noncompetitive blockade of N-methyl-D-aspartate receptors on the neurochemical sequelae of experimental brain injury. J Neurochem 55:1170-1179, 1990.
48. Morris GF, Juul N, Marshall SB, Benedict B, The Executive Committee of the International Selfotel Trial, Marshall LF: Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries. Neurosurgery 43:1369-1374, 1998.
49. Muizelaar JP, Dore-Duffy P: Advances in experimental research and clinical intervention for catastrophic brain injury: The early 21st century, in Levin HD, Eisenberg HM, Muizelaar JP (eds): Catastrophic Brain Injury. Oxford, UK, Oxford University Press, 1996, pp 233-252.
50. Muizelaar JP, Marmarou A, Young HF, Choi SC, Wolf A, Schneider RL, Kontos HA: Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycolconjugated superoxide dismutase: A Phase II trial. J Neurosurg 78:375-382, 1993.
51. 45Ca accumulation in rat brain after closed head injury: Attenuation by the novel neuroprotective agent HU-211. Brain Res 685:1-11, 1995.
52. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995.
53. Nordqvist AC, Holmin S, Nilsson M, Mathiesen T, Schalling M: MK-801 inhibits the cortical increase in IGF-1, IGFBP-2 and IGFBP-4 expression following trauma. Neuroreport 8:455-460, 1997.
54. Panter SS, Faden AI: Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury. Neurosci Lett 136:165-168, 1992.
55. Phillips LL, Lyeth BG, Hamm RJ, Jiang J-Y, Povlishock JT, Reeves TR: Effect of prior receptor antagonism on behavioral morbidity produced by combined fluid percussion injury and entorhinal cortical lesion. J Neurosci Res 49:197-206, 1997.
56. Povlishock JT, Christman CW: The pathobiology of traumatically induced axonal injury in animals and humans: A review of current thoughts. J Neurotrauma 12:555-564, 1995.
57. Schroder ML, Muizelaar JP, Bullock R, Povlishock JT, Salvant JB: Focal ischemia due to traumatic contusion documented by stable xenon CT and ultrastructural studies. J Neurosurg 82:966-971, 1994.
58. Schroder ML, Muizelaar JP, Kuta AJ: Documented reversal of global ischemia immediately after removal of an acute subdural hematoma. J Neurosurg 80:324-327, 1994.
59. Schwartz ML, Tator CH, Rowed DW, Reid SR, Meguro K, Andrews DF: The University of Toronto Head Injury Treatment Study: A prospective, randomized comparison of pentobarbital and mannitol. Can J Neurol Sci 11:434-440, 1984.
60. Shapira Y, Lam AM, Artru AA, Eng C, Soltow L: Ketamine alters calcium and magnesium in brain tissue following experimental head trauma in rats. J Cereb Blood Flow Metab 13:962-968, 1993.
61. Shapira Y, Yadid G, Cotev S, Niska A, Shohami E: Protective effect of MK801 in experimental brain injury. J Neurotrauma 7:131-139, 1990.
62. Shiozaki T, Sugimoto H, Taneda M, Yoshida H, Iwai A, Yoshioka T, Sugimoto T: Effect of mild hypothermia on uncontrollable intracranial hypertension after severe head injury. J Neurosurg 79:363-368, 1993.
63. Shohami E, Novikov M, Bass R: Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Res 674:55-62, 1995.
64. Shohami E, Novikov M, Mechoulam R: A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma 10:109-119, 1993.
65. Smith DH, Okiyama K, Gennarelli TA, McIntosh TK: Magnesium and ketamine attenuate cognitive dysfunction following experimental brain injury. Neurosci Lett 157:211-214, 1993.
66. Stein SC: Outcome from moderate head injury, in Narayan RK, Wilberger JE, Povlishock JT (eds): Neurotrauma. New York, McGraw-Hill, 1996, pp 755-765.
67. Teasdale G, Bailey I, Bell A, Gray J, Gullan R, Heiskanan O, Marks PV, Marsh H, Mendelow DA, Murray G, Ohman J, Quaghebeur G, Sinar J, Skene A, Teasdale G, Waters A: A randomized trial of nimodipine in severe head injury: HIT I - British/Finnish Cooperative Head Injury Trial Group. J Neurotrauma 9[Suppl 2]:S545-S550, 1992.
68. Teasdale GM, Pettigrew LEL, Wilson JTL, Murray WG, Jennett B: Analyzing outcome of treatment of severe head injury: A review and update on advancing the use of the Glasgow Outcome Scale. J Neurotrauma 15:587-597, 1998.
69. Tsuchida E, Harms JF, Woodward JJ, Bullock R: A use-dependent sodium channel antagonist, 619C89, in reduction of ischemic brain damage and glutamate release after acute subdural hematoma in the rat. J Neurosurg 85:104-111, 1996.
70. Tsuchida E, Rice M, Bullock R: The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma 14:409-417, 1997.
71. Unterberg A, Baethmann AJ: The kallikrein-kinin system as mediator in vasogenic brain edema: Part 1 - Cerebral exposure to bradykinin and plasma. J Neurosurg 61:87-96, 1984.
72. Unterberg A, Dautermann C, Baethmann A, Muller-Esteri W: The kallikrein-kinin system as mediator in vasogenic brain edema: Part 3 - Inhibition of the kallikrein-kinin system in traumatic brain swelling. J Neurosurg 61:269-276, 1986.
73. Verweij BH, Muizelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP: Mitochondrial dysfunction after experimental and human brain injury and its possible reversal with a selective N-type calcium antagonist (SNX-111). Neurol Res 19:334-339, 1997.
74. Ward A Jr: Atropine in the treatment of closed head injury. J Neurosurg 7:398-402, 1950.
75. Ward JD, Becker DP, Miller JD, Choi SC, Marmarou A, Wood C, Newlon PG, Keenan R: Failure of prophylactic barbiturate coma in the treatment of severe head injury. J Neurosurg 62:383-388, 1985.
76. Wilson JTL, Pettigrew LEL, Teasdale GM: Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: Guidelines for their use. J Neurotrauma 15:573-585, 1998.
77. Wolf AL, Levi L, Marmarou A, Ward JD, Muizelaar PJ, Choi S, Young H, Rigamonti D, Robinson WL: Effect of THAM upon outcome in severe head injury: A randomized prospective clinical trial. J Neurosurg 78:54-59, 1993.
78. Xiong Y, Gu Q, Peterson PL, Muizelaar JP, Lee CP: Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J Neurotrauma 14:23-34, 1997.
79. Xiong Y, Peterson PL, Muizelaar JP, Lee CP: Amelioration of mitochondrial function by a novel antioxidant U-101033E following traumatic brain injury in rats. J Neurotrauma 14:907-917, 1997.
80. Xiong Y, Peterson PL, Verweij BN, Vinas FC, Muizelaar JP, Lee CP: Mitochondrial dysfunction following experimental traumatic brain injury: Combined efficacy of SNX 111 and U-101033E. J Neurotrauma 15:531-544, 1998.
81. Yoshino A, Hovda DA, Kawamata T, Katayama Y, Becker DP: Dynamic changes in local cerebral glucose utilization following cerebral concussion in rats: Evidence of a hyper- and subsequent hypo-metabolic state. Brain Res 561:106-119, 1991.
82. Young B, Runge JW, Waxman KS, Harrington T, Wilberger J, Muizelaar JP, Boddy A, Kupiec JW: Effects of Pegorgotein on neurologic outcome of patients with severe head injury: A multicenter, randomized controlled trial. JAMA 276:538-543, 1996.